We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Blood Samples to Evaluate Biomarkers of Donor Chimerism

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00764829
First Posted: October 2, 2008
Last Update Posted: February 15, 2012
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
National Heart, Lung, and Blood Institute (NHLBI)
Information provided by:
Fred Hutchinson Cancer Research Center
  Purpose
We are interested in patient-specific factors that may affect the balance of recipient cells and donor cells in patients who receive stem cell transplants. We will look at the way the patient's body breaks down two drugs, fludarabine and mycophenolate mofetil, and how these two drugs affect the patient's body.

Condition
Leukemia Hodgkins Disease Non-hodgkins Lymphoma Myelodysplastic Syndrome

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Blood Samples to Evaluate Biomarkers of Donor Chimerism

Resource links provided by NLM:


Further study details as provided by Fred Hutchinson Cancer Research Center:

Primary Outcome Measures:
  • Donor T-cell chimerism [ Time Frame: Day 28 post-transplant ]

Secondary Outcome Measures:
  • Exposure to fludarabine and mycophenolate mofetil and their breakdown products. [ Time Frame: Before and after transplant ]

Biospecimen Retention:   Samples With DNA
plasma,DNA

Estimated Enrollment: 80
Study Start Date: September 2008
Study Completion Date: February 2012
Primary Completion Date: February 2012 (Final data collection date for primary outcome measure)
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Hematopoietic stem cell transplant patients receiving fludarabine and mycophenolate mofetil.
Criteria

Inclusion Criteria:

  • Diagnosed with a hematologic disease or malignancy
  • Scheduled to receive nonablative conditioning with fludarabine and total body irradiation
  • Donor is well-matched by high resolution DNA techniques.
  • Scheduled to receive postgrafting immunosuppression of oral MMF (CellCept) and an oral calcineurin inhibitor.
  • Age >18 years at the time of enrollment.

Exclusion criteria:

-Diagnosed with an immunodeficiency disorder

  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00764829


Locations
United States, Washington
Fred Hutchinson Cancer Research Center
Seattle, Washington, United States, 98109
Sponsors and Collaborators
Fred Hutchinson Cancer Research Center
National Heart, Lung, and Blood Institute (NHLBI)
Investigators
Principal Investigator: Jeannine S McCune, PharmD Fred Hutchinson Cancer Research Center
  More Information

Responsible Party: Jeannine S. McCune, PharmD, Fred Hutchinson Cancer Research Center
ClinicalTrials.gov Identifier: NCT00764829     History of Changes
Other Study ID Numbers: FHCRC - 1980.00
R01HL091744 ( U.S. NIH Grant/Contract )
IR-5957 ( Other Identifier: FHCRC )
First Submitted: September 30, 2008
First Posted: October 2, 2008
Last Update Posted: February 15, 2012
Last Verified: February 2012

Keywords provided by Fred Hutchinson Cancer Research Center:
hematopoietic stem cell transplantation
fludarabine
mycophenolate mofetil
mycophenolic acid
biomarkers

Additional relevant MeSH terms:
Myelodysplastic Syndromes
Preleukemia
Lymphoma, Non-Hodgkin
Hodgkin Disease
Bone Marrow Diseases
Hematologic Diseases
Precancerous Conditions
Neoplasms
Lymphoma
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases